We will investigate how the master control gene, Kruppel-like factor 1, orchestrates production of red blood cells. We will use genetic and cell biology approaches to determine exactly how this factor interprets the genome blueprint in a cell specific manner. We will also determine how mutations in KLF1 cause human diseases such as congenital dyserythropoietic anemia and hereditary persistence of fetal haemoglobin. This has implications for reactivation of HbF in adults with sickle cell disease.
Myelodysplastic Syndrome And The Bone Marrow Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$562,654.00
Summary
We are interested in how myelodysplastic syndrome (MDS) affects the function of the bone marrow. We believe that changes associated with anaemia of MDS cause the bone marrow to be altered. This proposal addresses this question and explores new treatment approaches
The Role Of Soluble Transferrin Receptor In The Regulation Of Iron Homeostasis
Funder
National Health and Medical Research Council
Funding Amount
$539,607.00
Summary
Iron is both essential for health and toxic in excess so the body very tightly regulates how much iron is absorbed from the diet. One of the most important regulators of dietary iron absorption is the iron demands of developing red blood cells. In this project we will investigate how developing red blood cells signal changes in iron absorption. An understanding of this process will be of great benefit in the analysis and treatment of important blood diseases and disorders of iron metabolism.
KLFs are master control genes that regulate the expression of many target genes to determine cell fate and to convert one cell fate to another. Mutations in KLFs cause human diseases. This grant will focus on the founding member of the KLF family, KLF1. We will use genomics techniques and animal models to determine how KLF1 works in normal blood cell production and in disease
IV Iron For Treatment Of Anaemia Before Cardiac Surgery (ITACS Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,285,290.00
Summary
Our aim is to evaluate intravenous iron to treat anaemia in 1000 patients waiting for their cardiac surgery. This could reduce the risks of the operation and enable patients to recover faster and can go home earlier.
A Randomised, Placebo-controlled Trial Of Oxpentifylline Versus Placebo In The Treatment Of Erythropoietin-resistant Anaemia In Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$345,189.00
Summary
Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatmen ....Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatments.Read moreRead less
Defining The Impact Of Universal Iron Interventions In Young Children: A Randomized Controlled Trial In Rural Bangladesh
Funder
National Health and Medical Research Council
Funding Amount
$2,794,373.00
Summary
Although nearly half of the world's young children are anaemic, evidence regarding the best approaches to correct this problem are limited. New data even suggests that the conventional approaches (iron supplements, multiple micronutrient powders) may even be harmful. We will perform the definitive trial which will confirm the existence and magnitude of any benefit (and harm) from these interventions in young Bangladeshi children. This trial will inform global policy on anaemia control.
Hemoglobin is the major protein in red blood cells and is essential for the transport of oxygen from the lungs to the tissues. The disorders of hemoglobin production are the commonest genetic diseases world-wide. These diseases can be markedly improved with elevation of the form of hemoglobin produced by the developing fetus, fetal hemoglobin. We have identified a key factor important for fetal gene expression. We will now determine whether manipulation of this factor can cure hemoglobin disorde ....Hemoglobin is the major protein in red blood cells and is essential for the transport of oxygen from the lungs to the tissues. The disorders of hemoglobin production are the commonest genetic diseases world-wide. These diseases can be markedly improved with elevation of the form of hemoglobin produced by the developing fetus, fetal hemoglobin. We have identified a key factor important for fetal gene expression. We will now determine whether manipulation of this factor can cure hemoglobin disorders.Read moreRead less
Benefits And Safety Of IRon Supplementation With MAlaria Chemoprevention To Children In Malawi (IRMA) - A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$3,064,309.00
Summary
Anaemia and malaria frequently coexist in low income settings e.g. sub-Saharan Africa and Asia. Iron interventions aim to reduce anaemia but exacerbate malaria. We aim to test whether iron is made safe by coadministering malaria prevention, and whether these interventions improve child health outcomes especially cognitive development, while ensuring malaria resistance does not emerge.
Transfusion Triggers In Cardiac Surgery Australia Trial (TRICS-III)
Funder
National Health and Medical Research Council
Funding Amount
$1,433,956.00
Summary
This study seeks to compare outcomes for cardiac surgery patients who are given a blood transfusion where the haemoglobin concentration is <7.5 or alternatively <9.5 g/dL. Blood transfusion is common in cardiac surgery and it is not known whether a more "restrictive" approach to blood transfusion has a different outcome. This will be the largest prospective randomised study of its kind, Australia contributing to a Canadian lead multi-centre international trial.